Why the study?
Chronic systemic inflammation contributes to both T2DM and CAD, but sVCAM-1 levels and their relationship to prior myocardial infarction in CAD patients with T2DM remained to be investigated.
Are sVCAM-1 levels elevated in patients with stable CAD and T2DM, and does this depend on a previous history of myocardial infarction?
Are sVCAM-1 levels elevated in patients with stable CAD and T2DM, and does this depend on a previous history of myocardial infarction?
Answers are grounded in this paper and cite their sources.
sVCAM-1 levels are elevated in CAD patients with T2DM regardless of prior MI, indicating persistent endothelial inflammation, whereas in CAD without T2DM, elevation is only seen in those with prior MI.
Chronic systemic inflammation is a key component of the pathogenesis of both type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). Soluble vascular cell adhesion molecule‑1 (sVCAM‑1) is considered as the indicator of vascular inflammation and endothelial activation. The aim of our study was to investigate sVCAM‑1 levels in patients with CAD with T2DM and to determine their dependence on a previous history of myocardial infarction (MI). The study included 52 patients with stable CAD with T2DM, 20 CAD patients without diabetes and 14 control group persons. sVCAM-1 levels were measured in serum by the enzyme-linked immunosorbent assay. sVCAM‑1 levels in patients with CAD with T2DM and patients with CAD without diabetes were higher than in the control group (p<0,001 and p<0,001, respectively). The difference in sVCAM‑1 levels between CAD patients with T2DM and without diabetes was not significant (p=0,355). There were no significant correlations of sVCAM‑1 levels with glucometabolic indices in any group. Only in patients with CAD with T2DM sVCAM‑1 level negatively correlated with high-density lipoprotein cholesterol. CAD patients with and without T2DM with a history of myocardial infarction (MI) had higher sVCAM‑1 levels than patients without previous MI (p=0,038, р=0,043, respectively). Only in diabetic CAD patients sVCAM‑1 levels were increased in those without a history of MI (р=0,036, in comparison with the controls). There were no correlations between sVCAM‑1 levels and left ventricular remodeling indices in patients either with or without MI. Conclusions. In patients with CAD with T2DM and patients with CAD without T2DM, sVCAM‑1 levels increased in comparison with the controls. However, in patients without diabetes sVCAM‑1 level was increased only in those with previous MI. In patients with T2DM, sVCAM‑1 level increased in the absence of previous MI and there was the further significant increase of its level in postinfarction cardiosclerosis.
No takes yet. Share an insight, caveat, or question.
Serik et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: